Novel PET imaging agents for understanding glutamine addiction in cancer
用于了解癌症中谷氨酰胺成瘾的新型 PET 成像剂
基本信息
- 批准号:8899339
- 负责人:
- 金额:$ 81.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-19 至 2017-07-31
- 项目状态:已结题
- 来源:
- 关键词:2-Fluoro-2-deoxyglucoseAcuteAmino AcidsBiodistributionBiologicalBiological MarkersCancer BiologyCancer PatientCell DeathCellsClinicCollaborationsComputational BiologyDependenceDetectionDevelopmentDiagnosisDown-RegulationERBB2 geneEnergy-Generating ResourcesEnzymesEvaluationExhibitsGene ExpressionGeneticGenetically Engineered MouseGlucoseGlutamineGlycolysisHumanImageImaging DeviceImaging technologyIn VitroIndividualLabelLaboratoriesLeadMalignant NeoplasmsMapsMediatingMetabolicMetabolic MarkerMetabolic PathwayMetabolic stressMetabolismMethodsModelingModificationMolecularMolecular TargetMonitorMusNutrientNutritionalOncogenesOncogenicPC3 cell linePaperPathway interactionsPennsylvaniaPositron-Emission TomographyPreparationRadiopharmaceuticalsReportingResearchRoleScienceSeriesSignal PathwaySourceSpecificitySystemSystems BiologyTestingTracerTransgenic MiceTranslationsTumor Cell LineUniversitiesUp-RegulationWritingaddictionantitumor agentbasec-myc Genescancer cellcellular targetingclinically relevantimaging agentin vivoin vivo imagingmalignant breast neoplasmmolecular imagingmouse modelneoplastic cellnoveloverexpressionpreferenceprogramsras Oncogeneresponsetargeted cancer therapytumortumor growthtumor metabolismuptake
项目摘要
This proposal is written in response to a RFA-CA-11-005 "Advanced In Vivo Imaging to
Understand Cancer Systems". Based on the needs of the proposed integrated research a multiple-
PI project will be used to maximize the potential of "team science" efforts on understanding of
changes of cancer metabolism. The collaboration between Chosdosh and Kung labs in the
University of Pennsylvania will provide a platform for integration of advanced in vivo PET
imaging technologies with system biology approaches to understand in vivo imaging of cancer.
The objective of this project is to prepare and evaluate 18F labeled glutamine derivatives for
diagnosis of tumor growth in cancer patients and to investigate the cancer biology associated
with the uptake of the novel tracers in cancer cells. In conjunction with positron emission
tomography (PET) these new probes may provide imaging tools for studying re-programming of
metabolic pathways for producing energy and building blocks to sustain proliferation of tumor
cells. Due to changing nutrient needs associated to tumor metabolism and proliferation, there is
a tumor specific increase in glycolysis and coordinated changes gene expression to maintain a
high rate of metabolism. The increase in glycolysis in major tumor types has been demonstrated
by FDG-PET. However, there is a significant fraction of active tumors that shows a negative
FDG uptake suggesting that the FDG-negative tumors may be using alternative sources of
energy and nutrient, such as glutamine and other amino acids. Recent reports indicate that there
are tumor cells, such as SF188 cells that display a high c-myc gene expression, which leads to a
high level of glutaminolysis. Reprogramming of genetic expression, up-regulation of the
oncogenes, such as c-Myc, HER2/neu, Wnt, Ras and Akt, and shifting of the energy source
associated with the proposed probes of tumor glutaminolysis and FDG-PET will be evaluated.
We will develop methods to prepare a series of 18F labeled glutamines and specific fine-tuning of
the oncogene expression in transgenic mice. The glutamines will be tested in tumor cells, such
as 9L, C6, PC3 and SF188 cells, which have demonstrated propensity for higher amino acid
uptake and glutaminolysis. Additionally, the tumor cell uptake will be correlated with oncogene
expression through the use of conditional transgenic mouse models for c-MYC, HER2/neu,
Wnt1, Ras and Akt overexpressing breast cancers. Successful glutamine imaging agents will be
selected for PET imaging of transgenic mice the tumors, in which metabolic changes showing
preference in using glutamine derivatives as the main source of nutrient. The proposed 18F
labeled glutamines may serve as new metabolic markers for probing glutamine-addictive tumors
not detected by FDG-PET. The development of the proposed alternative metabolic biomarkers
provides an exciting opportunity for advancing diagnosis and treatment of tumor. The novel
tumor metabolic imaging agents may lead to new methods to appraise the metabolic status of
tumor growth in human cancer and provide advancement of our understanding of tumor
oncogene expression and tumor metabolism by PET imaging.
本提案是根据RFA-CA-11-005“Advanced in Vivo Imaging to
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Chemistry. Expanding the scope of fluorine tags for PET imaging.
化学。
- DOI:10.1126/science.1245011
- 发表时间:2013
- 期刊:
- 影响因子:0
- 作者:Zhu,Lin;Ploessl,Karl;Kung,HankF
- 通讯作者:Kung,HankF
Alanine and glycine conjugates of (2S,4R)-4-[18F]fluoroglutamine for tumor imaging.
(2S,4R)-4-[18F]氟谷氨酰胺的丙氨酸和甘氨酸缀合物用于肿瘤成像。
- DOI:10.1016/j.nucmedbio.2018.02.001
- 发表时间:2018
- 期刊:
- 影响因子:3.1
- 作者:Zha,Zhihao;Ploessl,Karl;Lieberman,BrianP;Wang,Limin;Kung,HankF
- 通讯作者:Kung,HankF
Synthesis and evaluation of ¹⁸F labeled FET prodrugs for tumor imaging.
- DOI:10.1016/j.nucmedbio.2013.09.011
- 发表时间:2014-01
- 期刊:
- 影响因子:3.1
- 作者:Wang L;Lieberman BP;Ploessl K;Kung HF
- 通讯作者:Kung HF
Fluorination at the 4 position alters the substrate behavior of L-glutamine and L-glutamate: Implications for positron emission tomography of neoplasias.
- DOI:10.1016/j.jfluchem.2016.10.008
- 发表时间:2016-12
- 期刊:
- 影响因子:1.9
- 作者:Jeitner TM;Kristoferson E;Azcona JA;Pinto JT;Stalnecker C;Erickson JW;Kung HF;Li J;Ploessl K;Cooper AJL
- 通讯作者:Cooper AJL
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LEWIS A CHODOSH其他文献
LEWIS A CHODOSH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LEWIS A CHODOSH', 18)}}的其他基金
Radiogenomic Biomarkers of Breast Cancer Recurrence
乳腺癌复发的放射基因组生物标志物
- 批准号:
10161749 - 财政年份:2018
- 资助金额:
$ 81.16万 - 项目类别:
Radiogenomic Biomarkers of Breast Cancer Recurrence
乳腺癌复发的放射基因组生物标志物
- 批准号:
10403957 - 财政年份:2018
- 资助金额:
$ 81.16万 - 项目类别:
Secondary Prevention through Surveillance and Intervention
通过监测和干预进行二级预防
- 批准号:
9399635 - 财政年份:2016
- 资助金额:
$ 81.16万 - 项目类别:
Secondary Prevention through Surveillance and Intervention
通过监测和干预进行二级预防
- 批准号:
10051407 - 财政年份:2016
- 资助金额:
$ 81.16万 - 项目类别:
Novel PET imaging agents for understanding glutamine addiction in cancer
用于了解癌症中谷氨酰胺成瘾的新型 PET 成像剂
- 批准号:
8334480 - 财政年份:2011
- 资助金额:
$ 81.16万 - 项目类别:
Novel PET imaging agents for understanding glutamine addiction in cancer
用于了解癌症中谷氨酰胺成瘾的新型 PET 成像剂
- 批准号:
8546312 - 财政年份:2011
- 资助金额:
$ 81.16万 - 项目类别:
THE IMPACT OF EXERCISE AND CALORIC RESTRICTION ON CANCER RECURRENCE IN MICE
运动和热量限制对小鼠癌症复发的影响
- 批准号:
8072521 - 财政年份:2011
- 资助金额:
$ 81.16万 - 项目类别:
Novel PET imaging agents for understanding glutamine addiction in cancer
用于了解癌症中谷氨酰胺成瘾的新型 PET 成像剂
- 批准号:
8231824 - 财政年份:2011
- 资助金额:
$ 81.16万 - 项目类别:
Novel PET imaging agents for understanding glutamine addiction in cancer
用于了解癌症中谷氨酰胺成瘾的新型 PET 成像剂
- 批准号:
8733625 - 财政年份:2011
- 资助金额:
$ 81.16万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 81.16万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 81.16万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 81.16万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 81.16万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 81.16万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 81.16万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 81.16万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 81.16万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 81.16万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244994 - 财政年份:2023
- 资助金额:
$ 81.16万 - 项目类别:
Standard Grant














{{item.name}}会员




